W.WoldL
Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality weight loss with a cleaner tolerability profile
Since April 22, 2025, 503A enforcement discretion ended, and the FDA proposed in April 2026 to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List
There is some data indicating that weight loss medications may reduce the effectiveness of birth control pills, the most popular form of contraceptive in the United States
For weight management, the timing may be different
Clinic data suggests patients on sermorelin + GLP-1 preserve significantly more muscle than those on GLP-1 alone, with particular benefit for patients over 40 whose GH is already declining